•  
  •  
  •  
  •  

2026-05-08 15:28:45

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Brigade Enterprises Ltd announces 1:3 bonus issue
  • Aptus Value Housing Finance India Ltd declares 2nd interim dividend of Rs. 2.50
  • Gandhar Oil Refinery India Ltd completes purchase of land
  • eMudhra Ltd recommends final dividend of Rs. 1.25
  • Raymond Lifestyle Ltd recommends dividend of Rs. 1

Keywords Selected:  Approval

IPO News

  • SEBI Clears IPO for EAAA India Alternatives Ltd, Edelweiss Subsidiary to Launch ₹15,000 Million OFS
  • Rachit Prints Limited receives in-principle approval from BSE SME Exchange, Plans to Raise ₹19.50 Crore
  • Crizac Limited gets Sebi Nod for Rs 1,000 cr IPO
  • Jungle Camps India Limited plans to raise around Rs. 30 crores from IPO
  • Telangana-based Standard Glass Lining Technology Limited gets Sebi nod for IPO
  • IT Solutions provider Orient Technologies gets Sebi nod for IPO
  • Gala Precision Engineering gets Sebi nod for IPO
  • Noida-based Interarch Building Products Limited gets SEBI nod for IPO
  • Nephro Care India Limited plans to raise Rs. 35-40 crore from its upcoming IPO
  • Allied Blenders and Distillers Limited gets Sebi nod for Rs 1500 crore IPO
  • Sanstar Limited, gets SEBI nod to float IPO
  • Asirvad Micro Finance Limited gets Sebi nod for IPO
  • Kronox Lab Sciences gets SEBI nod to float IPO
  • Fairfax-backed Go Digit General Insurance gets Sebi nod for IPO
  • Gopal Snacks Limited gets Sebi nod for Rs 650 crore IPO
  • Juniper Hotels gets Sebi nod for its Rs 1,800 crore IPO
  • Stanley Lifestyles gets Sebi nod for IPO
  • Onest and Shiva Pharmachem gets Sebi nod for IPO
  • Mukka Proteins Limited gets Sebi Nod for IPO
  • Ludhiana-based Auto Component Maker Happy Forgings Limited receives Sebi nod to float its IPO
  • Cello World Limited gets Sebi nod for its Rs 1750 crore IPO
  • ESAF Small Finance Bank gets Sebi nod for IPO
  • MUFTI Owner Credo Brands Marketing gets Sebi nod for IPO
  • SAMHI Hotels and Motisons Jewellers gets Sebi nod for IPO

Stock Report

  • Motilal Oswal Asset Management Company Ltd receives PFRDA approval to act as Sponsor of Pension Fund
  • Steel Exchange India Ltd secures 5-Year Renewal of Approval from MES under the Ministry of Defence
  • Caplin Steriles Ltd gets USFDA approval for Calcium Gluconate Injection
  • Lupin Receives U.S. FDA Approval for Glycerol Phenylbutyrate Oral Liquid
  • Anuh Pharma Ltd receives WHO PQ approval for Amodiaquine Hydrochloride USP
  • Envair Electrodyne Ltd granted in-principle approval by IPICOL
  • OneSource Supports Second Generic Semaglutide Approval in Canada
  • OneSource's Partner Dr. Reddy's Laboratories receives Health Canada Approval for Generic Semaglutide Injection
  • MobiKwik Group secures RBI approval for NBFC application
  • Jagsonpal Pharmaceuticals Limited secures Shareholders' Approval for Buyback
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Fingolimod Capsules, 0.5 mg
  • Cipla Receives U.S. FDA Approval for First AB-Rated Generic of Ventolin® HFA
  • Omaxe Limited Secures RERA Approval for New Residential Project 'Omaxe Royal Nest' in Ludhiana
  • Kalyani Cast Tech Ltd receives approval of Layout Plan by Town Planning Authority
  • Biocon Receives Health Canada Approval of Bosaya™ and Vevzuo™, Biosimilars to Prolia® and Xgeva®
  • Orbicular's Partner secures tentative U.S. ANDA approval for a generic version of Semaglutide Injection, supported by OneSource as CDMO partner
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Methotrexate Injection USP
  • Shalby Hospitals' Krishna Unit Receives 5-Year Approval for Kidney Transplants
  • NHPC receives CCEA approval for investment in 1720 MW Kamala Hydro Electric Project
  • Lupin announces approval of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States
  • Zydus receives final approval from USFDA for Dapagliflozin Tablets, 5 mg and 10 mg
  • Biocon Pharma Ltd receives U.S. FDA Approval for Dapagliflozin Tablets, 5 mg and 10 mg
  • Aurobindo Pharma receives USFDA Approval for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets
  • Lupin Announces the Approval of Dapagliflozin Tablets in the United States

Industry News

  • ASK Asset & Wealth Management Group receives SEBI nod to launch its Mutual Fund business
  • Ashika Investment Managers Launches SmartAlpha Fund, a New Open-Ended Category III Data Strategy Fund
  • RBI grants NBFC license to Equirus Group
  • NCLT approves slice and North East Small Finance Bank's Merger
  • NSE launches WTI Crude Oil and Natural Gas futures contracts
  • Zero To One, an angel network, gets SEBI nod to launch INR 300cr Alternative Investment Fund
  • NTT DATA Payment Services accorded approval by RBI for payment aggregator license

Latest Post

  • Brigade Enterprises Ltd announces 1:3 bonus issue
  • Aptus Value Housing Finance India Ltd declares 2nd interim dividend of Rs. 2.50
  • Gandhar Oil Refinery India Ltd completes purchase of land
  • eMudhra Ltd recommends final dividend of Rs. 1.25
  • Raymond Lifestyle Ltd recommends dividend of Rs. 1


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025